Vasculitis & polymyalgia rheumatica
Serum calprotectin and renal function decline in antineutrophil cytoplasm antibody (ANCA)-associated vasculitides: a post hoc analysis of MAINRITSAN trial
Authors' conclusion
An increase in serum calprotectin by month 6 compared with inclusion during remission-maintenance therapy in AAV was associated with a higher risk of renal function decline in the following 12 months.
Study context
- Population
- AAV patients in complete remission after induction therapy, randomly assigned to RTX or AZA maintenance
- Participants
- 76 patients
- Comparison
- Increase vs no increase in serum calprotectin from inclusion to month 6
- Primary endpoint
- Renal function decline predicted by serum calprotectin levels
- Follow-up
- Following 12 months
Methodological detailspost hoc analysis
- Post hoc analysis
Primary result
As reported in the abstract
Change in serum calprotectin from baseline to month 6
Renal function decline
7940
range −226.0, 28 691 · ng/ml
No renal function decline
−4800
range −18 777, 3708 · ng/ml
P < 0.001
Further findings
Subsequent renal function decline with increase in calprotectin
| OR (95% CI) | P value | ||
|---|---|---|---|
| Calprotectin increaseEven after adjustment | 6.50 (1.7–24.9) | P = 0.006 | |
| 0.050.21520Odds ratio (log scale) |
Relapse in PR3-AAV with increase in serum calprotectin (subgroup)
| OR (95% CI) | P value | ||
|---|---|---|---|
| Calprotectin increase | 5.6 (1.0–31.2) | P = 0.03 | |
| 0.050.21520Odds ratio (log scale) |
Original publication
Serum calprotectin and renal function decline in ANCA-associated vasculitides: a post hoc analysis of MAINRITSAN trial. RMD Open. Published 30 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →